Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,732.00
Bid: 4,736.00
Ask: 4,739.00
Change: 78.00 (1.68%)
Spread: 3.00 (0.063%)
Open: 4,678.00
High: 4,775.00
Low: 4,649.00
Prev. Close: 4,654.00
CRDA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Technology acquisitions

11 Jan 2018 13:00

RNS Number : 6415B
Croda International PLC
11 January 2018
 

11 January 2018

 

Croda International plc ('Croda' or 'the Company')

 

Technology acquisitions

 

 

Croda International Plc, who make, create and sell innovative and sustainable speciality chemicals for some of the biggest, most successful brands in the world, has completed two technology acquisitions in exciting and novel application areas. This brings the number of technology acquisitions and co-investments completed in the last 12 months to four. Croda's technology acquisition programme supplements its development of new opportunities through organic investment and open innovation.

 

Nautilus Biosciences Canada Inc ('Nautilus'), is a technology-rich marine biotechnology company based in Charlottetown, Canada. Founded in 2007, Nautilus focuses on using marine microbial biodiversity to discover novel actives and materials. Through this acquisition and the associated patents, Croda will utilise this innovative science for applications across all its market sectors.

 

Croda and Nautilus already have a proven history of successful collaboration, having worked closely together for the past six years developing specific applications for skin care and hair care, as well as crop care. Croda intends to establish Nautilus as a Croda centre of innovation for Marine Biotechnology at Nautilus' existing base at the University of Prince Edward Island. This location is ideal for biotechnology research and has already attracted and facilitated partnerships with many other biotechnology-based companies. Nautilus has exclusive global access to the Marine Microbial Library which is based at the University of Prince Edward Island.

 

Croda has also completed the acquisition of IonPhasE Oy ('IonPhasE'), an innovative technology supplier of static electricity protection products, headquartered in Tampere, Finland.

 

Operating in some of the fastest growing segments within the plastics market, IonPhasE has developed a unique range of anti-static additives that help to prevent damage to electrical components, increase the safety of chemical and food packaging and improve the long-term appearance of consumer appliances. Focused on Electrostatic Discharge Protection (ESD) and Inherently Dissipative Polymers (IDPs), IonPhasE's products use the most advanced technologies in the static electricity protection market, which work to release static electricity in a controlled way.

 

These acquisitions follow the purchase of Enza Biotech AB in July 2017, a research enterprise in Sweden aiming to develop the next generation of renewable surfactants, together with an investment in Cutitronics Limited, a UK technology based innovator of personalised, adaptive skin care. These additional technology acquisitions support Croda's growth strategy within high technology, consumer driven markets, through exciting science-rich opportunities.

 

Steve Foots, Chief Executive of Croda, said: "These acquisitions are very much aligned to our strategy of investing in disruptive technologies, clever people and rich intellectual property. With Nautilus as part of the Croda group, we further expand our expertise in biotechnology; the Nautilus team that will join us have extensive knowledge and expertise in marine biotechnology, also known as "blue biotechnology". The experience and knowledge of the IonPhasE management team, coupled with our innovation strength, global sales reach and complementary technologies, will allow us to better meet the needs of our customers within our Smart Materials business within the Performance Technologies sector."

 

For enquiries contact:

Conleth Campbell, Head of Investor Relations: 01405 860551

Teneo Blue Rubicon: Charlie Armitstead: 020 3603 5220

 

About Croda - www.croda.com

Established in 1925, Croda is the name behind high performance ingredients and technologies in some of the world's biggest and most successful brands: creating, making and selling speciality chemicals that are relied on by industries and consumers everywhere.

They have a network of over 4,200 passionate and committed employees, working together as one global team across manufacturing sites and offices in 36 countries. Croda is a FTSE100 company with a flexible structure that allows them to focus on developing and delivering innovative, sustainable ingredients that their customers can build on in: Personal Care, Health Care, Crop Care, Polymer Additives, Lubricants, Coatings & Polymers, Geo Tech, Home Care and Industrial Specialities.

About Nautilus - www.nautilusbiosci.net

Nautilus Biosciences Canada is a marine biotechnology company located on the University of Prince Edward Island campus in Charlottetown, PEI. It aims to discover and develop bioactive agents from a marine microbial collection with applications focused on health and wellness.

About IonPhasE - www.ionphase.fi

Established in 2001, Finnish technology company IonPhasE is a leading manufacturer of static dissipative polymer additives, commonly known as permanent antistatic additives. These additives are used to control static electricity in plastics, which is utilised in wide range of global markets including electronics and semiconductor, chemical, food, automotive and consumer appliances.

 

About Enza Biotech - www.enzabiotech.com

Enza Biotech was founded in 2012 as a private spin-off company based on the results of a research programme coordinated by Lund University. A small, but highly innovative company, they combine insight into industrial challenges with a molecular understanding and knowledge of biotechnology based production methods.

The collaboration between biotechnology researchers and material scientists resulted in the design of a production process for a completely novel type of surfactant that meets the needs of many different markets.

About Cutitronics - www.cutitronics.com

Cutitronics is a multi-award winning technology company strategically white-labelling patented platforms and devices for global premium skin care brands in order to enhance consumer skincare routines through intelligent product application.

 

Cutitronics was spun-out of the University of Strathclyde in January 2014 by founder Dr David Heath and is located in Scottish Enterprise Technology Park, East Kilbride. 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQFKDDQBBKDFDD
Date   Source Headline
25th Apr 202410:01 amRNSResult of AGM
24th Apr 20247:00 amRNSFirst quarter 2024 sales update
11th Apr 20242:11 pmRNSDirector/PDMR Shareholding
8th Apr 202410:54 amRNSDirector/PDMR Shareholding
8th Apr 202410:23 amRNSDirector/PDMR Shareholding
28th Mar 20249:17 amRNSDirector/PDMR Shareholding
26th Mar 20244:19 pmRNSDirector/PDMR Shareholding
26th Mar 20244:10 pmRNSDirector/PDMR Shareholding
26th Mar 20244:09 pmRNSDirector/PDMR Shareholding
26th Mar 20244:09 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSDirector/PDMR Shareholding
26th Mar 20244:06 pmRNSDirector/PDMR Shareholding
26th Mar 20244:04 pmRNSDirector/PDMR Shareholding
15th Mar 20249:32 amRNSAnnual Financial Report
12th Mar 20242:49 pmRNSDirector/PDMR Shareholding
7th Mar 20243:03 pmRNSDirector/PDMR Shareholding
27th Feb 20247:00 amRNSResults for the year ended 31 December 2023
13th Feb 20243:35 pmRNSDirector/PDMR Shareholding
9th Feb 20243:28 pmRNSHolding(s) in Company
18th Jan 20241:33 pmRNSHolding(s) in Company
11th Jan 20243:17 pmRNSDirector/PDMR Shareholding
18th Dec 20237:00 amRNSDirectorate Change
12th Dec 20233:08 pmRNSDirector/PDMR Shareholding
11th Dec 202311:39 amRNSDirector Declaration
29th Nov 20234:54 pmRNSHolding(s) in Company
28th Nov 20239:35 amRNSDirector/PDMR Shareholding
24th Nov 202311:33 amRNSHolding(s) in Company
14th Nov 20239:40 amRNSDirector/PDMR Shareholding
19th Oct 202311:19 amRNSHolding(s) in Company
19th Oct 202310:34 amRNSDirector/PDMR Shareholding
12th Oct 202311:46 amRNSDirector/PDMR Shareholding
9th Oct 20237:00 amRNSThird Quarter Trading Update
6th Oct 20234:12 pmRNSDirector/PDMR Shareholding
5th Oct 20238:53 amRNSHolding(s) in Company
3rd Oct 20234:03 pmRNSDirector/PDMR Shareholding
27th Sep 20235:17 pmRNSDirector/PDMR Shareholding
26th Sep 202311:38 amRNSDirector/PDMR Shareholding
22nd Sep 20237:00 amRNSDirectorate Change
15th Sep 202311:51 amRNSDirector/PDMR Shareholding
12th Sep 20234:01 pmRNSDirector/PDMR Shareholding
12th Sep 20238:56 amRNSDirector/PDMR Shareholding
11th Aug 20232:26 pmRNSDirector/PDMR Shareholding
1st Aug 20237:13 amRNSDirector Declaration
25th Jul 20237:00 amRNSResults for the six months ended 30 June 2023
11th Jul 20232:57 pmRNSDirector/PDMR Shareholding
4th Jul 20238:02 amRNSCroda completes acquisition of Solus Biotech
26th Jun 202310:46 amRNSHolding(s) in Company
13th Jun 20233:55 pmRNSDirector/PDMR Shareholding
12th Jun 20232:06 pmRNSDirector/PDMR Shareholding
9th Jun 20237:00 amRNSTrading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.